Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs by Bastard, P, Vazquez, SE, Liu, J, Laurie, MT, Wang, CY, Gervais, A, Le Voyer, T, Le Voyer, T, Bizien, L, Zamecnik, C, Philippot, Q, Rosain, J, Catherinot, E, Willmore, A, Mitchell, AM, Bair, R, Garçon, P, Kenney, H, Fekkar, A, Salagianni, M, Poulakou, G, Siouti, E, Sahanic, S, Tancevski, I, Weiss, G, Nagl, L, Manry, J, Duvlis, S, Arroyo-Sánchez, D, Paz Artal, E, Rubio, L, Perani, C, Bezzi, M, Sottini, A, Quaresima, V, Roussel, L, Vinh, DC, Reyes, LF, Garzaro, M, Hatipoglu, N, Boutboul, D, Tandjaoui-Lambiotte, Y, Borghesi, A, Aliberti, A, Cassaniti, I, Venet, F, Monneret, G, Halwani, R, Sharif-Askari, NS, Danielson, J, Constantinescu, S

Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths by Bastard, P, Gervais, A, Le Voyer, T, Rosain, J, Philippot, Q, Manry, J, Michailidis, E, Hoffmann, H-H, Eto, S, Garcia-Prat, M, Bizien, L, Parra-Martínez, A, Yang, R, Haljasmägi, L, Migaud, M, Särekannu, K, Maslovskaja, J, de Prost, N, Tandjaoui-Lambiotte, Y, Luyt, C-E, Amador-Borrero, B, Gaudet, A, Poissy, J, Morel, P, Richard, P, Cognasse, F, Troya, J, Trouillet-Assant, S, Belot, A, Saker, K, Garçon, P, Rivière, JG, Lagier, J-C, Gentile, S, Rosen, LB, Shaw, E, Morio, T, Tanaka, J, Dalmau, D, Tharaux, P-L, Sene, D, Stepanian, A, Megarbane, B, Triantafyllia, V, Fekkar, A, Heath, JR, Franco, JL, Anaya, J-M, Solé-Violán, J, Imberti, L, Constantinescu, S